- Home
- MYGN vs RKT Comparison
MYGN vs RKT Comparison
Compare MYGN & RKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- RKT
- Stock Information
- Founded
- MYGN 1991
- RKT 1985
- Country
- MYGN United States
- RKT United States
- Employees
- MYGN N/A
- RKT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RKT Finance: Consumer Services
- Sector
- MYGN Health Care
- RKT Finance
- Exchange
- MYGN Nasdaq
- RKT Nasdaq
- Market Cap
- MYGN 2.0B
- RKT 2.3B
- IPO Year
- MYGN 1995
- RKT 2020
- Fundamental
- Price
- MYGN $13.69
- RKT $11.94
- Analyst Decision
- MYGN Hold
- RKT Sell
- Analyst Count
- MYGN 12
- RKT 11
- Target Price
- MYGN $23.92
- RKT $14.36
- AVG Volume (30 Days)
- MYGN 904.0K
- RKT 2.7M
- Earning Date
- MYGN 11-07-2024
- RKT 11-12-2024
- Dividend Yield
- MYGN N/A
- RKT N/A
- EPS Growth
- MYGN N/A
- RKT N/A
- EPS
- MYGN N/A
- RKT N/A
- Revenue
- MYGN $823,600,000.00
- RKT $4,304,653,000.00
- Revenue This Year
- MYGN $13.82
- RKT $15.88
- Revenue Next Year
- MYGN $4.59
- RKT $34.83
- P/E Ratio
- MYGN N/A
- RKT N/A
- Revenue Growth
- MYGN 12.15
- RKT 13.77
- 52 Week Low
- MYGN $13.81
- RKT $10.87
- 52 Week High
- MYGN $29.30
- RKT $21.38
- Technical
- Relative Strength Index (RSI)
- MYGN 26.49
- RKT 29.92
- Support Level
- MYGN $13.92
- RKT $12.06
- Resistance Level
- MYGN $15.44
- RKT $14.00
- Average True Range (ATR)
- MYGN 0.79
- RKT 0.45
- MACD
- MYGN 0.03
- RKT -0.05
- Stochastic Oscillator
- MYGN 3.06
- RKT 7.14
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About RKT Rocket Companies Inc.
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and is now the largest mortgage originator in the U.S. as well as the servicer for more than 2 million loans.